Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 8 |
| List of Tables | 5 | 3 |
| List of Figures | 8 | 3 |
| Men s Health Therapeutics Market to 2017 - Introduction | 11 | 1 |
| Overview | 11 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Men s Health Therapeutics Market to 2017 - Market Characterization | 12 | 12 |
| Overview | 12 | 1 |
| Market Forecasts | 13 | 1 |
| Global Generic/Off-label Share | 14 | 1 |
| Annual Cost of Treatment | 15 | 1 |
| Treatment Usage Patterns | 16 | 2 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 19 | 1 |
| Diagnosed Population | 20 | 1 |
| Treated Population | 21 | 1 |
| Drivers and Restraints of the Men s Health Therapeutics Market | 22 | 1 |
| Market Drivers | 22 | 1 |
| Market Restraints | 23 | 1 |
| Men s Health Therapeutics Market To 2017 - Geographical Landscape | 24 | 16 |
| Market Forecasts by Country | 24 | 2 |
| The US | 26 | 1 |
| Market Forecasts | 26 | 1 |
| Annual Cost of Treatment | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Diseased Population | 29 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Treated Population | 29 | 1 |
| Top Five Countries in Europe | 30 | 1 |
| Market Forecasts | 30 | 2 |
| Annual Cost of Treatment | 32 | 1 |
| Treatment Usage Patterns | 33 | 1 |
| Diseased Population | 34 | 1 |
| Treatment Seeking Population | 34 | 1 |
| Diagnosed Population | 34 | 1 |
| Treated Population | 34 | 1 |
| Japan | 35 | 1 |
| Market Forecasts | 35 | 1 |
| Annual Cost of Treatment | 36 | 1 |
| Treatment Usage Patterns | 37 | 1 |
| Diseased Population | 38 | 1 |
| Treatment Seeking Population | 38 | 1 |
| Diagnosed Population | 38 | 1 |
| Treated Population | 39 | 1 |
| Men s Health Therapeutics Market to 2017 - Therapeutic Landscape | 40 | 45 |
| Global Erectile Dysfunction (ED) Therapeutics Market | 40 | 1 |
| Market Overview | 40 | 1 |
| Market Forecasts | 40 | 2 |
| Revenue Analysis by Country | 42 | 2 |
| Global Generic/Off-Label Share | 44 | 1 |
| Annual Cost of Treatment | 45 | 1 |
| Treatment Flow Algorithm | 46 | 1 |
| Treatment Usage Patterns | 47 | 1 |
| Diseased Population | 48 | 1 |
| Treatment Seeking Population | 48 | 1 |
| Diagnosed Population | 48 | 1 |
| Treated Population | 49 | 1 |
| Product Analysis | 49 | 1 |
| Viagra (sildenafil citrate) | 49 | 1 |
| Cialis (tadalafil) | 49 | 1 |
| Levitra (vardenafil HCL) | 50 | 1 |
| Muse (alprostadil) | 50 | 1 |
| Drivers and Restraints of the ED Therapeutics Market | 50 | 1 |
| Market Drivers | 50 | 1 |
| Market Restraints | 51 | 1 |
| Global Male Hypogonadism Therapeutics Market | 51 | 1 |
| Market Overview | 51 | 1 |
| Market Forecasts | 52 | 1 |
| Revenue Analysis by Country | 53 | 2 |
| Global Generic/Off-label Share | 55 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Treatment Flow Algorithm | 57 | 1 |
| Treatment Usage Patterns | 58 | 1 |
| Diseased Population | 59 | 1 |
| Treatment Seeking Population | 59 | 1 |
| Diagnosed Population | 60 | 1 |
| Treated Population | 60 | 1 |
| Product Analysis | 61 | 1 |
| Gels (AndroGel, Testim and Fortesta) | 61 | 1 |
| Injections (Depo-Testosterone, Nebido, Delatestryl): | 62 | 1 |
| Transdermals (Androderm, Testoderm, Axiron) | 62 | 1 |
| Buccal Tablet (Striant) | 62 | 1 |
| Pellet Implants | 62 | 1 |
| Drivers and Restraints of the Male Hypogonadism Therapeutics Market | 63 | 1 |
| Market Drivers | 63 | 1 |
| Market Restraints | 63 | 1 |
| Global Premature Ejaculation (PE) Therapeutics Market | 63 | 1 |
| Market Overview | 63 | 1 |
| Market Forecasts | 64 | 1 |
| Revenue by Country | 65 | 2 |
| Global Generic/Off-Label Share | 67 | 1 |
| Annual Cost of Treatment | 68 | 1 |
| Treatment Flow Algorithm | 69 | 1 |
| Treatment Usage Patterns | 70 | 1 |
| Diseased Population | 71 | 1 |
| Treatment Seeking Population/Diagnosed Population | 71 | 1 |
| Treated Population | 71 | 1 |
| Product Analysis | 72 | 1 |
| Prozac/Sarafem (fluoxetine) | 72 | 1 |
| Paxil (paroxetine) | 72 | 1 |
| Zoloft (sertraline) | 72 | 1 |
| Priligy (dapoxetine) | 72 | 1 |
| Anafranil (clomipramine) | 72 | 1 |
| Lidocaine/prilocaine cream (EMLA cream) | 73 | 1 |
| Drivers and Restraints of the PE Therapeutics Market | 73 | 1 |
| Market Drivers | 73 | 1 |
| Market Restraints | 73 | 1 |
| Global Benign Prostatic Hyperplasia (BPH) Market | 74 | 1 |
| Overview | 74 | 1 |
| Market Forecasts | 74 | 2 |
| Revenue Analysis by Country | 76 | 1 |
| Generics/Off-Label Share | 77 | 1 |
| Annual Cost of Treatment | 78 | 1 |
| Treatment Flow Algorithm | 79 | 1 |
| Treatment Usage Patterns | 80 | 1 |
| Diseased Population | 81 | 1 |
| Treatment Seeking Population | 82 | 1 |
| Diagnosed Population | 82 | 1 |
| Treated Population | 82 | 1 |
| Product Analysis | 83 | 1 |
| Avodart (dutasteride) | 83 | 1 |
| Flomax (tamsulosin hydrochloride) | 83 | 1 |
| Cardura (doxazosin mesylate) | 83 | 1 |
| Uroxatral (Alfuzosin hydrochloride) | 83 | 1 |
| Drivers and Restraints of the BPH Therapeutics Market | 84 | 1 |
| Market Drivers | 84 | 1 |
| Market Restraints | 84 | 1 |
| Men s Health Therapeutics Market to 2017 - Pipeline Analysis | 85 | 19 |
| Overview | 85 | 1 |
| Research and Development Pipeline by Indication | 85 | 2 |
| Research and Development by Phase of Development | 87 | 1 |
| Research and Development Pipeline - Erectile Dysfunction | 88 | 1 |
| Pipeline by Clinical Phases of Development | 89 | 1 |
| Discovery | 89 | 1 |
| Preclinical/IND Filed | 89 | 1 |
| Phase I | 89 | 1 |
| Phase II | 89 | 1 |
| Phase III | 90 | 1 |
| NDA Filed | 90 | 1 |
| Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market | 90 | 1 |
| Avanafil | 90 | 1 |
| Zoraxel | 91 | 1 |
| Vitaros | 92 | 1 |
| Zydena (udenafil, DA-8159) | 92 | 1 |
| Research and Development Pipeline - Premature Ejaculation | 93 | 1 |
| Pipeline by Clinical Phases of Development | 94 | 1 |
| Discovery | 94 | 1 |
| Preclinical | 94 | 1 |
| Phase I | 94 | 1 |
| Phase II | 94 | 1 |
| Phase III | 95 | 1 |
| Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market | 95 | 1 |
| PSD502/TEMPE | 95 | 1 |
| Research and Development Pipeline - Male Hypogonadism | 96 | 1 |
| Pipeline by Clinical Phases of Development | 97 | 1 |
| Preclinical | 97 | 1 |
| Phase I | 97 | 1 |
| Phase II | 97 | 1 |
| NDA Filed | 98 | 1 |
| Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market | 98 | 1 |
| Bio-T-Gel | 98 | 1 |
| Aveed (testosterone Undecanoate) | 98 | 1 |
| Research and Development Pipeline - Benign Prostatic Hyperplasia | 99 | 1 |
| Pipeline by Clinical Phases of Development | 100 | 1 |
| Preclinical | 100 | 1 |
| Phase I | 100 | 1 |
| Phase II | 101 | 1 |
| Phase III | 101 | 1 |
| NDA Filed | 102 | 1 |
| Profiles of Key Late-Stage Drugs in the Benign Prostatic Hyperplasia Market | 102 | 1 |
| NX-1207 | 102 | 1 |
| PRX302 | 103 | 1 |
| Men s Health Therapeutics Market to 2017 - Competitive Landscape | 104 | 9 |
| Overview | 104 | 1 |
| Company Profiles | 104 | 1 |
| Pfizer Inc. | 104 | 1 |
| Business Overview | 104 | 1 |
| SWOT Analysis | 104 | 1 |
| Eli Lilly and Company | 105 | 1 |
| Business Overview | 105 | 1 |
| SWOT Analysis | 105 | 1 |
| Men s Health Product Pipeline | 105 | 1 |
| GlaxoSmithKline, Inc | 106 | 1 |
| Business Overview | 106 | 1 |
| SWOT Analysis | 106 | 1 |
| Men s Health Product Pipeline | 106 | 1 |
| Abbott Laboratories | 107 | 1 |
| Business Overview | 107 | 1 |
| SWOT Analysis | 107 | 1 |
| Men s Health Product Pipeline | 107 | 1 |
| Endo Pharmaceuticals Holding Inc. | 108 | 1 |
| Business Overview | 108 | 1 |
| SWOT Analysis | 108 | 1 |
| Men s Health Product Pipeline | 108 | 1 |
| Bayer Healthcare AG | 109 | 1 |
| Business Overview | 109 | 1 |
| SWOT Analysis | 109 | 1 |
| Men s Health Product Pipeline | 109 | 1 |
| Johnson &Johnson | 110 | 1 |
| Business Overview | 110 | 1 |
| SWOT Analysis | 110 | 1 |
| VIVUS, Inc. | 111 | 1 |
| Business Overview | 111 | 1 |
| SWOT Analysis | 111 | 1 |
| Men s Health Product Pipeline | 111 | 1 |
| Auxilium Pharmaceuticals, Inc. | 112 | 1 |
| Business Overview | 112 | 1 |
| SWOT Analysis | 112 | 1 |
| Men s Health Therapeutics Market to 2017 - Strategic Consolidations | 113 | 10 |
| Overview | 113 | 1 |
| Mergers and Acquisitions | 114 | 1 |
| Overview | 114 | 1 |
| Deals by Deals Value | 114 | 1 |
| Deals by Geography | 115 | 1 |
| Deals by Year | 116 | 1 |
| Major M&A Deals | 117 | 1 |
| Licensing Agreements | 118 | 1 |
| Deals by Geography | 118 | 1 |
| Deals by Value | 119 | 1 |
| Deals by Year | 120 | 1 |
| Major Licensing Agreements | 121 | 1 |
| Co-Development Deals | 122 | 1 |
| Major Co-Development Deals | 122 | 1 |
| Men s Health Therapeutics Market to 2017 - Appendix | 123 | 8 |
| Market Definitions | 123 | 1 |
| Abbreviations | 123 | 1 |
| Research Methodology | 124 | 6 |
| Coverage | 124 | 1 |
| Secondary Research | 125 | 1 |
| Primary Research | 125 | 1 |
| Therapeutic Landscape | 126 | 1 |
| Epidemiology-based Forecasting | 126 | 2 |
| Market Size by Geography | 128 | 1 |
| Geographical Landscape | 129 | 1 |
| Pipeline Analysis | 129 | 1 |
| Competitive Landscape | 129 | 1 |
| Expert Panel Validation | 129 | 1 |
| Contact Us | 129 | 1 |
| Disclaimer | 129 | 1 |
| Sources | 130 | 1 |